Healthcare Industry News: SonoLysis
News Release - October 24, 2006
ImaRx Therapeutics, Inc. Announces Management Team Changes
TUCSON, Ariz.--(HSMN NewsFeed)--ImaRx Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing therapies for vascular disorders associated with blood clots, today announced that Dr. Evan Unger has resigned as President and Chief Executive Officer so that he will have more time to devote to the scientific development of the Company. The Board wishes to thank Dr. Unger for his contributions. The Company's Board of Directors has created the Office of the CEO and has appointed Brad Zakes and Greg Cobb to staff the office on an interim basis. Mr. Zakes and Mr. Cobb will retain their roles as the Company's Chief Operating Officer and Chief Financial Officer respectively.Dr. Unger will remain a member of the ImaRx Board of Directors and will head the Company's Scientific Advisory Board.
The Company's Board of Directors has initiated a CEO search.
About ImaRx Therapeutics
The "Clotbusting" Company(TM).
ImaRx Therapeutics is developing and commercializing therapies for vascular disorders associated with blood clots based on two platforms, urokinase-based thrombolytics and SonoLysis, a therapy combining our proprietary bubbles with ultrasound to treat stroke, and other vascular diseases. At ImaRx, our goal is to improve patient outcomes by restoring critical blood flow to vital organs and tissues such as the brain and lungs following acute ischemic or thrombotic events.
Source: ImaRx Therapeutics
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
